Guadecitabine vs TC in relapsed/refractory AML after intensive chemotherapy: a randomized phase 3 ASTRAL-2 trial.

Guadecitabine vs TC in relapsed/refractory AML after intensive chemotherapy: a randomized phase 3 ASTRAL-2 trial. Blood Adv. 2024 04 23; 8(8):2020-2029.

View in: PubMed

subject areas

Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols
Azacitidine
Cytarabine
Drug Resistance, Neoplasm
Female
Humans
Leukemia, Myeloid, Acute
Male
Middle Aged
Recurrence
Treatment Outcome
Young Adult

authors with profiles

Wendy Stock